» Articles » PMID: 30755812

A Novel CD7 Chimeric Antigen Receptor-modified NK-92MI Cell Line Targeting T-cell Acute Lymphoblastic Leukemia

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2019 Feb 14
PMID 30755812
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a challenge since most target antigens are shared between normal and malignant cells, leading to CAR-T cell fratricide. CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL), but it is not expressed in one small group of normal T lymphocytes. Here, we constructed monovalent CD7-CAR-NK-92MI and bivalent dCD7-CAR-NK-92MI cells using the CD7 nanobody VHH6 sequences from our laboratory. Both CD7-CAR-NK-92MI and dCD7-CAR-NK-92MI cells consistently showed specific and potent anti-tumor activity against T-cell leukemia cell lines and primary tumor cells. We observed robust cytotoxicity of the bivalent mdCD7-CAR-NK-92MI monoclonal cells against primary T-ALL samples. In agreement with the enhanced cytotoxicity of mdCD7-CAR-NK-92MI cells, significant elevations in the secretion of Granzyme B and interferon γ (IFN-γ) were also found in mdCD7-CAR-NK-92MI cells in response to CD7-positive primary T-ALL cells compared with NK-92MI-mock cells. Furthermore, we also demonstrated that mdCD7-CAR-NK-92MI cells significantly inhibited disease progression in xenograft mouse models of T-ALL primary tumor cells. Our data suggest that CD7-CAR-NK-92MI cells can be used as a new method or a complementary therapy for treating T-cell acute lymphocytic leukemia.

Citing Articles

CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.

Zhi L, Zhang Z, Gao Q, Shang C, He W, Wang Y BMC Cancer. 2025; 25(1):337.

PMID: 40000974 PMC: 11853679. DOI: 10.1186/s12885-025-13780-2.


Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.

Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M Transfus Med Hemother. 2025; 52(1):42-60.

PMID: 39944413 PMC: 11813277. DOI: 10.1159/000540962.


Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies.

Lajevardi M, Ashrafpour M, Mubarak S, Rafieyan B, Kiani A, Noori E Med Oncol. 2024; 42(1):11.

PMID: 39572459 PMC: 11582151. DOI: 10.1007/s12032-024-02547-7.


A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?.

Andrea A, Chiron A, Sarrabayrouse G, Bessoles S, Hacein-Bey-Abina S Front Immunol. 2024; 15:1459818.

PMID: 39430751 PMC: 11486669. DOI: 10.3389/fimmu.2024.1459818.


Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies.

Zhou S, Yang Y, Jing Y, Zhu X Front Immunol. 2024; 15:1435635.

PMID: 39372412 PMC: 11449748. DOI: 10.3389/fimmu.2024.1435635.


References
1.
Khalidi H, Chang K, Medeiros L, Brynes R, Slovak M, Arber D . Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol. 1999; 111(4):467-76. DOI: 10.1093/ajcp/111.4.467. View

2.
Tam Y, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann H . Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999; 10(8):1359-73. DOI: 10.1089/10430349950018030. View

3.
Tam Y, Miyagawa B, Ho V, Klingemann H . Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother. 1999; 8(3):281-90. DOI: 10.1089/106161299320316. View

4.
Campana D, Behm F . Immunophenotyping of leukemia. J Immunol Methods. 2000; 243(1-2):59-75. DOI: 10.1016/s0022-1759(00)00228-3. View

5.
Muyldermans S, Cambillau C, Wyns L . Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci. 2001; 26(4):230-5. DOI: 10.1016/s0968-0004(01)01790-x. View